Radiofrequency Ablation and Alternative Ablative Methods for Chronic Facet Joint Mediated Neck, Back and Sacroiliac Joint Pain
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Iowa policy alerts
Know when Blue Cross Blue Shield - Iowa releases new policies or updates existing guidance.
Monitor payer policy activity
Wellmark (Blue Cross Blue Shield - Iowa) medical policy on RFA and alternative ablative methods (e.g., cooled RFA, cryodenervation, chemical neurolysis, pulsed RFA, endoscopic RFA, laser denervation) for chronic sacroiliac joint (SIJ) pain and chronic facet joint–mediated neck and back pain, summarizing evidence, regulatory status, and coverage position including prior approval requirements.
Prior approval requirement is stated.
Policy underwent Annual Review and was Renewed in January 2026.
Coverage Summary
Overview: This Wellmark coverage criteria addresses radiofrequency ablation (RFA) and alternative ablative methods for chronic sacroiliac joint (SIJ) pain and chronic facet joint–mediated neck and back pain. Policy status is mixed (investigational for specified indications) with an effective date of 2022-07-01 and last review/renewal on 2026-01-01. Prior authorization is required for procedures covered under this policy. Radiofrequency ablation for chronic SIJ pain is considered investigational, and listed alternative ablative methods (e.g., chemical neurolysis, cooled RFA, cryodenervation, endoscopic RFA, laser denervation, pulsed RFA) are considered investigational for chronic facet joint or SIJ pain.
Coverage Determinations & Criteria
Coverage Determinations
Policy coverage positions:
ALL of the following
- Prior approval is required.
Policy explicitly states prior approval requirement.
Investigational / Not covered when ANY of the following procedures are requested for stated indications
- RFA SIJ: Radiofrequency ablation (RFA) for the treatment of chronic sacroiliac joint (SIJ) pain is considered investigational.
The evidence is insufficient to determine improvement in net health outcome.
- Chemical neurolysis (chemodenervation; e.g., alcohol, phenol, glycerol, or hypertonic solution)
Listed as investigational alternative ablative method.
- Cooled radiofrequency
Listed as investigational alternative ablative method.
- Cryodenervation (cryoablation)
Listed as investigational alternative ablative method.
- Endoscopic RFA: Endoscopic radiofrequency ablation
Listed as investigational alternative ablative method.
- Laser denervation
Listed as investigational alternative ablative method.
- Pulsed RFA: Pulsed radiofrequency (PRF) ablation
Listed as investigational alternative ablative method.
Procedure Codes & Place/Type of Service
| 64625 | Radiofrequency ablation, nerves innervating the sacroiliac joint, with image guidance (i.e., fluoroscopy or computed tomography). |
| 64633 | Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, single facet joint. |
| 64635 | Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, single facet joint. |
| Type of Service: Surgery | Indicates procedure classification as surgical/service type. |
| Place of Service: Outpatient/Inpatient | Place of service indicated as outpatient or inpatient. |
Required Provider Actions & Documentation
Prior approval required
Prior approval is required for procedures covered by this policy.
Investigational procedures are not considered medically necessary
Claims for radiofrequency ablation (RFA) for sacroiliac joint (SIJ) pain and for listed alternative ablative methods (e.g., chemical neurolysis, cooled RFA, cryodenervation/cryoablation, endoscopic RFA, laser denervation, pulsed RFA) may be denied as investigational because the evidence is insufficient to demonstrate an improvement in net health outcome.
Evidence and diagnostic confirmation
Document diagnostic confirmation and relevant prior treatments when submitting medical necessity requests: include findings of diagnostic workup for SIJ or facet-mediated pain, documentation of prior conservative therapy, and the patient’s response to diagnostic anesthetic injections/blocks.
Diagnostic block evidence
Document results of appropriate diagnostic blocks before proceeding with RFA or other ablative procedures. Controlled SIJ blocks are commonly considered diagnostic with at least 75% pain relief; for lateral sacral branch blocks some societies recommend a threshold of 50% or greater pain reduction prior to advancing to radiofrequency procedures.
Follow-up monitoring
Follow-up monitoring and documentation of outcomes is recommended for 6 to 12 months after alternative ablative procedures to monitor symptom recurrence and the need for additional treatments; record pain, function, and quality-of-life measures.
Use appropriate CPT/HCPCS/ICD codes
Use appropriate procedure and diagnosis codes when reporting services; CPT codes listed in this policy include 64625, 64633, and 64635 — select the CPT/HCPCS/Revenue and ICD diagnosis codes that accurately describe the service and indication per the policy.
- CPT 64625: Radiofrequency ablation, nerves innervating the sacroiliac joint, with image guidance.
- CPT 64633: Destruction by neurolytic agent, paravertebral facet joint nerve(s); cervical or thoracic, single facet joint.
- CPT 64635: Destruction by neurolytic agent, paravertebral facet joint nerve(s); lumbar or sacral, single facet joint.
Evidence Summary & Background
Background summary: The policy reviews systematic reviews, randomized controlled trials (RCTs), observational studies, and case series of RFA and alternative ablative methods for chronic SIJ and facet joint–mediated pain. Meta-analyses and sham-controlled RCTs indicate small short-term (1–3 month) pain and function benefits in some trials, particularly for cooled RFA in selected studies, but trials are heterogeneous and have methodological limitations (small samples, variable techniques, short follow-up). Limited long-term data exist and one RCT with 6–12 month follow-up showed no significant benefit versus exercise. Overall, evidence is insufficient to conclude a consistent net health benefit for many techniques. Regulatory note: multiple RF and cryoneurolysis devices have been cleared by FDA via 510(k) (examples listed in the policy’s device table).
| Evidence Item | Summary |
|---|---|
| RCTs for SIJ RFA | |
| Six randomized controlled trials and case series identified; meta-analyses of sham‑controlled RCTs suggest a small short‑term (1–3 month) effect on SIJ pain but methodologic limitations, heterogeneity of techniques, and limited long‑term data lead to insufficient evidence of net health benefit. | |
| Systematic reviews | |
| Multiple systematic reviews (e.g., Janapala 2024, Chou 2021, Ciaffi 2024) report low‑to‑moderate quality evidence with high heterogeneity, short follow‑up in many studies, and insufficient long‑term data to draw firm conclusions. | |
| Cooled RFA (Cohen et al. 2023) | |
| Multicenter single‑blind RCT (n=210) showed significant improvements at 3 months in NRS, ODI, SF‑36 PCS, EQ‑5D‑5L, and PGIC; 41.9% vs 6.5% achieved ≥50% pain relief (p<.0001); 15% procedure‑related AEs, none severe; limitations include single‑blind design and short follow‑up. | |
| Patel et al. (2012;2016) | |
| Randomized double‑blind sham‑controlled lateral branch cooled RFA (n=51 randomized 2:1) showed at 3 months significant pain and function improvements and 47% vs 12% achieved ≥50% NRS reduction; response durable to 12 months in completers; some crossover and attrition noted. | |
| McCormick et al. (2019) | |
| Small RCT (n=43) comparing traditional RFA vs cooled RFA for lumbar facet pain found no significant difference in responder rates at 6 months; limited by small sample and short follow‑up. | |
| Meta-analysis conclusion | |
| Sham‑controlled RCT meta‑analyses indicate modest short‑term benefit (1–3 months) of RFA for SIJ pain, but heterogeneity, variable techniques, and limited durability data limit generalizability and confidence in long‑term benefit. | |
| Alternative ablative methods overall | |
| Evidence for laser denervation, chemical neurolysis, cryoablation, pulsed RFA, and endoscopic RFA is low‑quality with small samples and short follow‑up; insufficient to establish safety and efficacy for chronic facet or SIJ pain. | |
| Regulatory | |
| Multiple RF and cryoneurolysis devices have FDA 510(k) clearance (examples listed in device table) and CPT codes for reporting procedures are provided (e.g., 64625; neurolytic agent codes 64633/64635 listed). |
Definitions (glossary): Chemical neurolysis (chemodenervation) – injection of neurolytic agents (e.g., phenol, alcohol, glycerol, hypertonic solution) to denervate nerves. Cooled RFA (CRFA) – water-cooled radiofrequency probe producing larger, spherical lesions to ablate larger tissue volumes. Cryodenervation (cryoablation) – use of extreme cold (e.g., −170°C CO2) to destroy pain-transmitting nerves. Endoscopic RFA – minimally invasive endoscopic transection and ablation of medial branch nerves under direct visualization. Laser denervation – use of high-intensity laser energy to denervate target nerves. Pulsed radiofrequency (PRF) – short bursts of RF current with temperatures ≤ 42°C intended to modulate nerve transmission without permanent thermal lesioning. SIJ – sacroiliac joint. RFA – radiofrequency ablation (thermal neurotomy). TRFA – traditional/thermal radiofrequency ablation.
Clinical Thresholds & Responder Definitions
Policy Revision History
Policy became effective (Original Effective Date: July 2022).
Policy text clarified to state: Prior approval is required. (Prior approval requirement is stated.)
Annual Review and policy renewed in January 2026.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.